Santen to Present Latest Data on Omidenepag Isopropyl at AGS 2022

1 March 3rd, 2022 Santen to Present Latest Data on Omidenepag Isopropyl at AGS 2022 Santen Pharmaceutical Co., Ltd. ( Head Office in Osaka, hereinafter “Santen”) announced today that a publication of EP2 receptor agonist, omidenepag isopropyl, will be presented at the American Glaucoma Society’s annual meeting (AGS 2022; https://www.americanglaucomasociety.net/ags-events/annual- meeting) from March 3rd to 6th, 2022. Omidenepag isopropyl has been sold in Japan and Asia since 2018 as EYBELIS Ophthalmic Solution 0.002%, a treatment for glaucoma and ocular hypertension. In the United States, Santen is preparing for resubmission of the New Drug Application at the end of March 2022. Presentation topic Poster # Title 3149 IOP lowering effect of omidenepag isopropyl (OMDI) versus latanoprost or timolol in the Phase 3 PEONY and Spectrum 4 studies: 3-month subgroup analyses of the effect of age, sex, diagnosis, and prior medication Contact: Investor Relations Group Santen Pharmaceutical Co., Ltd. E-mail: [email protected]

The release as fetched from its publisher. santen.com ↗